OS Therapies Inc (AMEX: OSTX)’s stock price has dropped by -28.40 in relation to previous closing price of 4.12. Nevertheless, the company has seen a loss of -40.64% in its stock price over the last five trading days. seekingalpha.com reported 2025-01-16 that OSTX’s OST-HER2 immunotherapy is in a fully enrolled phase 2b trial for osteosarcoma, which had an updated readout in mid-January 2025. Financially, OSTX has $7.9 million in cash, with recent funding providing a runway until 2026, but remains poorly capitalized and reliant on near-term news. Strengths include a mid-stage product for an unmet need, but risks involve past failures of Listeria-based immunotherapies and uncertain funding prospects.
Is It Worth Investing in OS Therapies Inc (AMEX: OSTX) Right Now?
Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for OSTX is 14.12M, and at present, short sellers hold a 0.38% of that float. On January 20, 2025, the average trading volume of OSTX was 376.19K shares.
OSTX’s Market Performance
OSTX stock saw a decrease of -40.64% in the past week, with a monthly decline of -15.23% and a quarterly a decrease of -6.05%. The volatility ratio for the week is 39.96%, and the volatility levels for the last 30 days are 29.90% for OS Therapies Inc (OSTX). The simple moving average for the past 20 days is -32.38% for OSTX’s stock, with a -10.64% simple moving average for the past 200 days.
OSTX Trading at -9.00% from the 50-Day Moving Average
After a stumble in the market that brought OSTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.86% of loss for the given period.
Volatility was left at 29.90%, however, over the last 30 days, the volatility rate increased by 39.96%, as shares sank -37.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.32% upper at present.
During the last 5 trading sessions, OSTX fell by -40.64%, in comparison to the 20-day moving average, which settled at $4.36. In addition, OS Therapies Inc saw -31.07% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OSTX starting from Auerbach Shalom, who sale 16,720 shares at the price of $6.74 back on Jan 15 ’25. After this action, Auerbach Shalom now owns 2,531,211 shares of OS Therapies Inc, valued at $112,609 using the latest closing price.
Stock Fundamentals for OSTX
The total capital return value is set at 8.24.
Currently, EBITDA for the company is -4.34 million with net debt to EBITDA at 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.76.
Conclusion
To sum up, OS Therapies Inc (OSTX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
